[go: up one dir, main page]

PE20160562A1 - Tienouracilcarboxamidas ciclicas y usos de las mismas - Google Patents

Tienouracilcarboxamidas ciclicas y usos de las mismas

Info

Publication number
PE20160562A1
PE20160562A1 PE2016000459A PE2016000459A PE20160562A1 PE 20160562 A1 PE20160562 A1 PE 20160562A1 PE 2016000459 A PE2016000459 A PE 2016000459A PE 2016000459 A PE2016000459 A PE 2016000459A PE 20160562 A1 PE20160562 A1 PE 20160562A1
Authority
PE
Peru
Prior art keywords
methyl
same
compounds
hydroxypiperidin
thieno
Prior art date
Application number
PE2016000459A
Other languages
English (en)
Inventor
Martina Delbeck
Michael Harter
Bernd Kalthof
Pierre Wasnaire
Niels Lindner
Klemens Lustig
Frank Sussmeier
Raimund Kast
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20160562A1 publication Critical patent/PE20160562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a compuestos de formula (I), en donde: R1 es H, metilo, entre otros; R2 es metilo, etilo, entre otros; R3 es alquilo(C1-C6), alquenilo (C2-C6), entre otros; el anillo A es un aza heterociclo mono o biciclico de la formula i), ii), entre otros. Son compuestos preferidos: 6- [(4-Hidroxipiperidin-1-il)carbonil -5-metil-3-(2-feniletil)-1-(3, 3, 3 -trifluoropropil)tieno-[2,3-d]pirimidina-2,4(1H,3H)-diona; 1-(4,4-Difluorobut-3-en-1-il)-6-[(4-hidroxipiperidin-1-il)carbonil]-5-metil-3-(2-feniletil)tieno[2,3-d]pirimidina-2,4(1H,3H)-diona; entre otros. Estos compuestos actuan como antagonistas potentes y selectivos del receptor A2b de la adenosina siendo utiles para el tratamiento de trastornos pulmonares y cardiovasculares
PE2016000459A 2013-10-07 2014-10-02 Tienouracilcarboxamidas ciclicas y usos de las mismas PE20160562A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13187487 2013-10-07
EP14152518 2014-01-24

Publications (1)

Publication Number Publication Date
PE20160562A1 true PE20160562A1 (es) 2016-06-05

Family

ID=51655757

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000459A PE20160562A1 (es) 2013-10-07 2014-10-02 Tienouracilcarboxamidas ciclicas y usos de las mismas

Country Status (24)

Country Link
US (2) US9604996B2 (es)
EP (1) EP3055313B1 (es)
JP (1) JP2016532721A (es)
KR (1) KR20160065957A (es)
CN (1) CN105793267B (es)
AP (1) AP2016009128A0 (es)
AU (1) AU2014334040A1 (es)
BR (1) BR112016007238A2 (es)
CA (1) CA2926223A1 (es)
CR (1) CR20160155A (es)
CU (1) CU20160044A7 (es)
DO (1) DOP2016000076A (es)
EA (1) EA201600318A1 (es)
ES (1) ES2659043T3 (es)
IL (1) IL244751A0 (es)
MX (1) MX2016004250A (es)
NI (1) NI201600047A (es)
PE (1) PE20160562A1 (es)
PH (1) PH12016500608A1 (es)
SG (1) SG11201602397XA (es)
TN (1) TN2016000121A1 (es)
TW (1) TW201607950A (es)
UY (1) UY35771A (es)
WO (1) WO2015052065A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170313665A1 (en) * 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
CA3030021A1 (en) * 2016-07-07 2018-01-11 Cardurion Pharmaceuticals, Llc Methods for treatment of heart failure
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
MX2019003351A (es) * 2016-09-23 2019-08-05 Bayer Ag Tienouracilos n3-ciclicamente sustituidos y uso de los mismos.
WO2024037532A1 (zh) * 2022-08-16 2024-02-22 深圳市康哲生物科技有限公司 一种噻吩并嘧啶酮衍生物的盐型及晶型

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DK1107973T3 (da) * 1998-08-28 2004-02-23 Astrazeneca Ab Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
BR0207216A (pt) 2001-02-14 2004-03-09 Warner Lambert Co Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1467995B1 (en) * 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
JP2009528389A (ja) * 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
BRPI0712516A2 (pt) * 2006-05-18 2016-08-23 Hoffmann La Roche compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b
CA2670788A1 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2008115912A1 (en) 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US7947629B2 (en) * 2007-08-06 2011-05-24 Schlumberger Technology Corporation Method of acidizing sandstone formations
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
US8673891B2 (en) 2009-02-06 2014-03-18 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AU2011275825A1 (en) 2010-07-09 2013-02-07 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2776038B1 (en) 2011-11-11 2018-01-10 Gilead Apollo, LLC Acc inhibitors and uses thereof

Also Published As

Publication number Publication date
PH12016500608A1 (en) 2016-06-13
BR112016007238A2 (pt) 2017-08-01
TW201607950A (zh) 2016-03-01
IL244751A0 (en) 2016-04-21
CU20160044A7 (es) 2016-09-30
CA2926223A1 (en) 2015-04-16
DOP2016000076A (es) 2016-05-15
MX2016004250A (es) 2016-07-12
AU2014334040A1 (en) 2016-04-28
KR20160065957A (ko) 2016-06-09
ES2659043T3 (es) 2018-03-13
NI201600047A (es) 2016-09-21
TN2016000121A1 (en) 2017-10-06
SG11201602397XA (en) 2016-05-30
EP3055313A1 (de) 2016-08-17
CN105793267A (zh) 2016-07-20
EP3055313B1 (de) 2017-11-22
US20160244461A1 (en) 2016-08-25
US9604996B2 (en) 2017-03-28
WO2015052065A1 (de) 2015-04-16
UY35771A (es) 2015-04-30
US20170145029A1 (en) 2017-05-25
CN105793267B (zh) 2018-02-06
CR20160155A (es) 2016-07-21
JP2016532721A (ja) 2016-10-20
EA201600318A1 (ru) 2016-09-30
AP2016009128A0 (en) 2016-04-30

Similar Documents

Publication Publication Date Title
PE20160562A1 (es) Tienouracilcarboxamidas ciclicas y usos de las mismas
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
SV2011003997A (es) Pirimidinas fusionadas
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
PE20180116A1 (es) HETEROCICLILMETIL-TIENOURACILO COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2b
CL2016000398A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
BR112015024907A2 (pt) n-acil-(3-substituido)-(8-substituido)-5,6-dihidro-[1,2,4]triazol[4,3a]pirazinas como antagonistas receptores seletivos de nk-3, composição farmacêutica, métodos para uso em desordens mediadas por receptores de nk-3
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PH12013502445A1 (en) Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
PE20200016A1 (es) Imidazopirimidinas diazabiciclicas sustituidas y su uso para el tratamiento de trastornos respiratorios
CR20150424A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
PE20150777A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
EA201490579A1 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
PE20170640A1 (es) Derivados de quinolizinona como inhibidores de pi3k
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2016000387A1 (es) Derivados de amida como antagonistas de ácido receptor lisofosfatidico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal